Dyno taking partner-heavy strategy with next-generation gene therapy vectors

With a $9M seed round and two deals, Dyno may not need to raise any more private capital

After two years in stealth mode, modestly-funded Dyno believes its synthetic capsid engineering platform will be best used by partners to feed their gene therapy pipelines with optimized candidates -- including two biopharmas that have already struck deals with the start-up.

On Monday, Dyno Therapeutics Inc. revealed $9 million in initial funding and partnerships

Read the full 532 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers